Spero Therapeutics (SPRO) EBIAT (2016 - 2025)
Historic EBIAT for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to -$7.4 million.
- Spero Therapeutics' EBIAT rose 5684.38% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.9 million, marking a year-over-year decrease of 136915.29%. This contributed to the annual value of -$68.6 million for FY2024, which is 40079.8% down from last year.
- According to the latest figures from Q3 2025, Spero Therapeutics' EBIAT is -$7.4 million, which was up 5684.38% from -$1.7 million recorded in Q2 2025.
- In the past 5 years, Spero Therapeutics' EBIAT registered a high of $51.2 million during Q4 2023, and its lowest value of -$32.8 million during Q1 2022.
- Moreover, its 5-year median value for EBIAT was -$13.9 million (2025), whereas its average is -$10.8 million.
- Its EBIAT has fluctuated over the past 5 years, first surged by 19141.85% in 2022, then plummeted by 43500.78% in 2024.
- Quarter analysis of 5 years shows Spero Therapeutics' EBIAT stood at -$29.3 million in 2021, then skyrocketed by 191.42% to $26.8 million in 2022, then soared by 91.27% to $51.2 million in 2023, then plummeted by 140.82% to -$20.9 million in 2024, then surged by 64.59% to -$7.4 million in 2025.
- Its last three reported values are -$7.4 million in Q3 2025, -$1.7 million for Q2 2025, and -$13.9 million during Q1 2025.